Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its 2mg generic Dienogest tablets, the generic equivalent of Visanne, for treatment of pelvic pain associated with endometriosis.
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its 2mg generic Dienogest tablets, the generic equivalent of Visanne, for treatment of pelvic pain associated with endometriosis.
The company cites Dataintelo, which values the global Dienogest market at $2.8 billion in 2025, projected to reach $5.2 billion by 2034 with a 7.8% CAGR. Canada represents about 2.1% of the global pharmaceutical market and ranks sixth worldwide. Sunshine Biopharma will distribute Dienogest through its wholly owned Canadian subsidiary Nora Pharma and expects product availability for pharmacies by the end of 2026.
According to Sunshine Biopharma, the approval expands its women’s health portfolio. The company currently markets 60 generic prescription drugs in Canada, plans about 12 additional launches in 2026, and is also developing K1.1 mRNA for liver cancer and a PLpro protease inhibitor for SARS coronavirus infections.
Positive
- Canadian approval of 2mg generic Dienogest tablets for endometriosis-related pelvic pain
- Entry into global Dienogest market valued at $2.8 billion in 2025
- Target market projected to reach $5.2 billion by 2034 with 7.8% CAGR
- Established Canadian distribution via wholly owned subsidiary Nora Pharma
- 60 generic drugs already marketed in Canada, with ~12 more launches planned in 2026
Negative
- None.
News Explained
Although the headline describes entry into the
Details
Market reaction after Canadian regulatory approval: SBFM +11.97% in the Aug 4 session
In the Aug 4 session, SBFM gained 11.97%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.4% during that session. Argus tracked a trough of -7.6% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 16.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Dienogest dosage
- 2mg
- Generic tablets approved for Canada
- Global Dienogest market
- $2.8 billion
- 2025 market value
- Projected Dienogest market
- $5.2 billion
- Projected market value by 2034
- Market CAGR
- 7.8%
- Global Dienogest market projection
- Canadian pharmaceutical market share
- 2.1%
- Share of global pharmaceutical market
- Canadian market ranking
- sixth largest
- Worldwide pharmaceutical market ranking
- Generic prescription drugs
- 60
- Currently on the market in Canada
- Additional scheduled launches
- 12
- Scheduled for the remainder of 2026
Historical Context
-
Health Canada approved generic ondansetron tablets for the Canadian market.
-
Peer-reviewed research reported broad-spectrum PLpro inhibitor activity in preclinical models.
-
Canadian regulators approved generic anastrozole tablets equivalent to Arimidex.
-
Canadian approval expanded Sunshine Biopharma’s generic anticoagulant portfolio.
-
A U.S. patent covered small-molecule compounds targeting coronavirus PLpro.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dienogest medical
progesterone receptor binding medical
cagr financial
mRNA-Lipid Nanoparticle technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dienogest is first-line therapy for pelvic pain associate with endometriosis
The endometriosis treatment market is projected to reach
$5.2 billion by 2034
FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne®.
Dienogest works through progesterone receptor binding, local anti-inflammatory actions, and mild hormone suppression. It reduces endometriosis pain by shrinking abnormal tissue growth.
According to Dataintelo, the global Dienogest market was valued at
Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Dienogest represents a strategic expansion for the Company into the area of women's health with first-line therapy for pelvic pain associated with endometriosis. The Company anticipates that its Dienogest will be ready to ship to pharmacies by the end of 2026.
"We are pleased to introduce Dienogest oral tablets as the newest addition to our expanding portfolio of high-quality generic medicines," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "With Dienogest widely used for the management of pelvic pain associated with endometriosis, this approval strengthens our position in the women's health market and underscores our commitment to delivering reliable therapies that meet critical patient needs."
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.